Collaboration Agreements - Additional Information (Detail) - USD ($)			3 Months Ended					6 Months Ended		12 Months Ended
	Nov. 30, 2020	Jun. 30, 2018	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Jun. 30, 2022	Jun. 30, 2018	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2020	Jun. 12, 2018
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue			$ 2,474,000			$ 1,501,000		$ 5,768,000	$ 3,082,000
Related Party [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration receivable - related party			15,090,000		$ 13,660,000			15,090,000
Collaboration Revenue [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue			14,000					14,000
Shionogi Collaboration Agreement [Member] | Collaboration Revenue [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue								0	0
Shionogi Collaboration Agreement [Member] | SAGE-217 [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment		$ 90,000,000.0
Average percentage on tiered royalties		20.00%
Revenue							$ 90,000,000.0
Standalone selling price of license performance obligation		$ 90,000,000.0					90,000,000.0
Shionogi Collaboration Agreement [Member] | SAGE-217 [Member] | Maximum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Additional milestone payment receivable		485,000,000.0					$ 485,000,000.0
Shionogi Collaboration Agreement [Member] | SAGE-217 [Member] | Maximum [Member] | Regulatory Milestones [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Future milestone payments		70,000,000.0
Shionogi Collaboration Agreement [Member] | SAGE-217 [Member] | Maximum [Member] | Commercial Milestones [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Future milestone payments		30,000,000.0
Shionogi Collaboration Agreement [Member] | SAGE-217 [Member] | Maximum [Member] | Sales Milestones [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Future milestone payments		$ 385,000,000.0
Biogen Collaboration Agreement [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement effective date	Dec. 28, 2020
Upfront payment										$ 875,000,000.0
Revenue								0	0	1,100,000,000
Standalone selling price of license performance obligation										1,100,000,000
Sale of stock, consideration received										$ 1,500,000,000
Public offering of common stock, net of offering costs, Shares										6,241,473
Purchase price										$ 650,000,000.0
Operating expenses			14,900,000			$ 23,800,000		29,200,000	$ 43,800,000
Payments to related parties								0
Proceeds from related parties				$ 27,800,000	$ 27,800,000
Biogen Collaboration Agreement [Member] | Related Party [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration receivable - related party			$ 15,100,000					$ 15,100,000
Biogen Collaboration Agreement [Member] | SAGE-217 [Member] | Maximum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Additional milestone payment receivable											$ 1,600,000,000
Biogen Collaboration Agreement [Member] | SAGE-217 [Member] | Maximum [Member] | First Commercial Sale of Zurzuvae for Treatment of MDD [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Future milestone payments	$ 150,000,000
Biogen Collaboration Agreement [Member] | SAGE-217 [Member] | Maximum [Member] | First Commercial Sale of Zurzuvae for Treatment of PPD [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Future milestone payments	75,000,000
Biogen Collaboration Agreement [Member] | SAGE-217 [Member] | Maximum [Member] | Sales Milestones [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Future milestone payments	300,000,000.0
Biogen Collaboration Agreement [Member] | SAGE-217 [Member] | Maximum [Member] | Regulatory and Commercial Milestones [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Future milestone payments	475,000,000.0
Biogen Collaboration Agreement [Member] | SAGE-324 [Member] | Maximum [Member] | Sales Milestones [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Future milestone payments	300,000,000.0
Biogen Collaboration Agreement [Member] | SAGE-324 [Member] | Maximum [Member] | Regulatory and Commercial Milestones [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Future milestone payments	$ 520,000,000.0
Biogen Stock Purchase Agreement [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment										875,000,000.0
Purchase price										650,000,000.0
Transaction price, total										1,100,000,000
Premium amount on equity investment										$ 232,500,000
Price per share										$ 104.14
Premium on per share price										40.00%
Biogen stock purchase agreement, description								The standstill restrictions terminate on the earliest of (i) a specified regulatory milestone under the Biogen Collaboration Agreement, (ii) the date one year following the termination of the Biogen Collaboration Agreement and (iii) the seventh anniversary of the Effective Date. BIMA also agreed not to, and to cause its affiliates not to, sell or transfer any of the Biogen Shares for a period of eighteen months from the closing of the sale of the Biogen Shares, which period expired on June 30, 2022, and to limit sales and transfers of the Biogen Shares for an additional eighteen-month period, which expires December 31, 2023, in each case subject to specified conditions and exceptions.
Stock issued										$ 417,500,000